Alphabet-backed Isomorphic Labs has raised $5 billion in a funding round co-led by Greenoaks and Sequoia Capital, giving the AI drug discovery company additional resources to advance its first experimental treatments towards clinical trials.
The financing marks a major capital commitment to the application of artificial intelligence in pharmaceutical research, where companies are seeking to use computational models to shorten the process of identifying and designing potential medicines. Isomorphic, founded by Google DeepMind chief Demis Hassabis, is working to move its internal drug programmes beyond laboratory testing and into human trials.
The company, which was spun out of Google DeepMind in 2021, did not disclose its valuation. The new investment comes roughly six months after it raised $2.1 billion in a Series B round led by Thrive Capital, taking its recent fundraising to more than $7 billion.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Andreessen Horowitz and other new investors joined the latest round. Alphabet made a significant investment, while existing backers including Thrive Capital, MGX and GV also participated.
The scale of the financing gives Isomorphic substantial capital to develop its drug-design technology and advance programmes in oncology and immunology. It also signals continued investor interest in AI companies seeking to apply computational advances to industries with lengthy research timelines and high development costs.
“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” Hassabis said.
Isomorphic is developing its IsoDDE drug design engine, which uses AI to design potential medicines, predict their properties, and refine candidates before scientists select compounds for production and testing.
The approach aims to improve the early stages of drug development by helping researchers assess potential molecules computationally before committing resources to laboratory experiments. Identifying promising candidates and predicting how they may behave can be a costly and time-consuming process, making the ability to narrow the field a potentially valuable application of AI.
However, computational predictions and pre-clinical results are not evidence that a drug will work in patients. Experimental medicines must still pass through clinical trials to establish their safety, effectiveness and appropriate dosage. Many candidates fail during this process, even after showing encouraging results in laboratory and animal studies.
Isomorphic said it has recorded positive pre-clinical results in internal oncology and immunology programmes, as well as work conducted with partners. The company said these results were “setting the stage for clinical entry,” although it did not disclose specific drug candidates, trial timelines or detailed efficacy data in its announcement.
Moving into clinical development will therefore be an important test of the company’s technology. Its ability to design molecules is one measure of progress, but the more consequential question is whether those designs can produce treatments that demonstrate meaningful benefits in patients.
The backdrop matters for investors assessing the commercial potential of AI drug discovery. Pharmaceutical research can generate substantial returns when a treatment succeeds, but the path from an initial molecular design to an approved medicine involves years of testing, regulatory review and significant financial risk.
Isomorphic’s partnerships with established drugmakers provide another route for applying its technology. Its website lists Novartis, Eli Lilly and Johnson & Johnson among its partners.
These relationships connect the company’s computational research with pharmaceutical groups that have experience in drug development and clinical testing. They also provide opportunities to apply its technology to disease areas where established companies have research programmes and expertise.
For the pharmaceutical industry, AI-assisted drug design could improve the efficiency of early research and help identify candidates that might otherwise take longer to discover. But the value of the technology is ultimately tied to the quality of the medicines it helps produce, not simply the speed at which it generates potential molecules.
The latest funding gives Isomorphic more capacity to pursue that objective while developing its underlying models. It also places pressure on the company to demonstrate that its technology can deliver results beyond computational predictions and pre-clinical experiments.
With its first therapeutic programmes approaching clinical development, Isomorphic is entering a stage where scientific claims will face more demanding tests. The $5 billion investment provides the resources to advance that work, but clinical outcomes will determine how much of the promise of AI-designed medicines can turn into commercial treatments.



